HNSP.F Stock Overview
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Hansoh Pharmaceutical Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.88 |
| 52 Week High | HK$1.88 |
| 52 Week Low | HK$1.50 |
| Beta | 0.51 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 2.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| HNSP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 0.7% |
| 1Y | n/a | 12.1% | 32.2% |
Return vs Industry: Insufficient data to determine how HNSP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how HNSP.F performed against the US Market.
Price Volatility
| HNSP.F volatility | |
|---|---|
| HNSP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HNSP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HNSP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 9,123 | Huijuan Zhong | www.hspharm.com |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors.
Hansoh Pharmaceutical Group Company Limited Fundamentals Summary
| HNSP.F fundamental statistics | |
|---|---|
| Market cap | US$13.32b |
| Earnings (TTM) | US$451.75m |
| Revenue (TTM) | US$1.39b |
29.5x
P/E Ratio9.6x
P/S RatioIs HNSP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSP.F income statement (TTM) | |
|---|---|
| Revenue | CN¥10.10b |
| Cost of Revenue | CN¥1.03b |
| Gross Profit | CN¥9.07b |
| Other Expenses | CN¥5.79b |
| Earnings | CN¥3.28b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 89.78% |
| Net Profit Margin | 32.44% |
| Debt/Equity Ratio | 16.4% |
How did HNSP.F perform over the long term?
See historical performance and comparison